

Specimen ID: 007-316-5331-0

Acct #: 09357925

Phone: (813) 445-7342

Rte: 00

Specimen Details

Date collected: 01/07/2020 1516 Local

Date received: 01/07/2020

Date entered: 01/07/2020

Date reported: 01/13/2020 0706 ET

General Comments & Additional Information

Alternate Control Number: B0097929707

Total Volume: Not Provided

Alternate Patient ID: NOT PROVIDED

Fasting: No

Ordered Items

Testosterone, Free and Total; Dihydrotestosterone; DHEA-Sulfate; Estradiol, Sensitive; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Testosterone, Free and Total					
Testosterone, Serum	650		ng/dL	264 - 916	01
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Free Testosterone (Direct)	11.3		pg/mL	6.6 - 18.1	02
Dihydrotestosterone					
	50		ng/dL		03
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. Reference Range: Adult Male: 30 - 85					
DHEA-Sulfate	598.7	High	ug/dL	30.9 - 295.6	01
Estradiol, Sensitive	8.9		pg/mL	8.0 - 35.0	02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration. Methodology: Liquid chromatography tandem mass spectrometry (LC/MS/MS)					

01	CB	LabCorp Dublin 6370 Wilcox Road, Dublin, OH 43016-1269	Dir: Vincent Ricchiuti, PhD
02	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
03	ES	Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358	Dir: Samuel Pepkowitz, MD

For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-282-7300

Specimen ID: 007-316-5509-0
Control ID: 42182370586

Acct #: 12018330

Phone: (630) 912-2910

Rte: 00

Northwest Suburban Urologists

Specimen Details

Date collected: 01/07/2020 1525 Local
Date received: 01/07/2020
Date entered: 01/07/2020
Date reported: 01/08/2020 1007 ET

mation

Fasting: N

Ordered Items

Prostate-Specific Ag, Serum; Non LCA Req

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Prostate-Specific Ag, Serum

Prostate Specific Ag, Serum	4.1	High	ng/mL	0.0 - 4.0	01
-----------------------------	-----	------	-------	-----------	----

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

01	CB	LabCorp Dublin 6370 Wilcox Road, Dublin, OH 43016-1269	Dir: Vincent Ricchiuti, PhD
----	----	---	-----------------------------

For inquiries, the physician may contact Branch: 800-597-8026 Lab: 800-282-7300

Specimen ID: 319-305-9490-0
Control ID: B0096379496

Acct #: 09357925

Phone: (813) 445-7342

Rte: 00

Defy Medical LLC

Specimen Details

Date collected: 11/15/2019 1130 Local
Date received: 11/15/2019
Date entered: 11/15/2019
Date reported: 11/20/2019 0811 ET

nation
06

Alternate F
Fasting: Yes

Total Volume: Not Provided

Ordered Items

PSA Total+% Free; Vitamin B12 and Folate; Testosterone, Free and Total; C-Reactive Protein, Cardiac; Estradiol, Sensitive; Uric Acid; Progesterone; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

PSA Total+% Free

Prostate Specific Ag, Serum	3.8		ng/mL	0.0 - 4.0	01
-----------------------------	-----	--	-------	-----------	----

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

PSA, Free	1.05		ng/mL	N/A	01
-----------	------	--	-------	-----	----

Roche ECLIA methodology.

% Free PSA	27.6		%		
------------	------	--	---	--	--

The table below lists the probability of prostate cancer for men with non-suspicious DRE results and total PSA between 4 and 10 ng/mL, by patient age (Catalona et al, JAMA 1998, 279:1542).

% Free PSA	50-64 yr	65-75 yr
0.00-10.00%	56%	55%
10.01-15.00%	24%	35%
15.01-20.00%	17%	23%
20.01-25.00%	10%	20%
>25.00%	5%	9%

Please note: Catalona et al did not make specific recommendations regarding the use of percent free PSA for any other population of men.

Vitamin B12 and Folate

Vitamin B12	438		pg/mL	232 - 1245	01
Folate (Folic Acid), Serum	10.2		ng/mL	>3.0	01

Note:

A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency.

Date Issued: 12/04/19 1231 ET

FINAL REPORT

Page 1 of 2

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error, please call 800-282-7300

© 1995-2019 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00

Patient Report

pl ID: B0096379496

Specimen ID: 319-305-9490-0
Date collected: 11/15/2019 1130 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Testosterone, Free and Total					
Testosterone, Serum	1067	High	ng/dL	264 - 916	01
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Free Testosterone(Direct)	18.8	High	pg/mL	6.6 - 18.1	02
C-Reactive Protein, Cardiac					
	1.25		mg/L	0.00 - 3.00	01
Relative Risk for Future Cardiovascular Event					
Low				<1.00	
Average				1.00 - 3.00	
High				>3.00	
Estradiol, Sensitive					
	25.5		pg/mL	8.0 - 35.0	02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration.					
Methodology: Liquid chromatography tandem mass spectrometry(LC/MS/MS)					
Uric Acid					
Uric Acid	5.8		mg/dL	3.7 - 8.6	01
Please Note:					
Therapeutic target for gout patients: <6.0					
Progesterone					
	0.5		ng/mL	0.0 - 0.5	01
01 CB	LabCorp Dublin			Dir: Vincent Ricchiuti, PhD	
	6370 Wilcox Road, Dublin, OH 43016-1269				
02 BN	LabCorp Burlington			Dir: Sanjai Nagendra, MD	
	1447 York Court, Burlington, NC 27215-3361				

For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-282-7300

Date Issued: 12/04/19 1231 ET

FINAL REPORT

Page 2 of 2

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-282-7300

© 1995-2019 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00